Tau PET imaging in aging and early Alzheimer’s disease

By Keith A. Johnson, A. Schultz, Rebecca A. Betensky, J. Becker, Jorge Sepulcre, Dorene M. Rentz, Elizabeth C. Mormino, J. Chhatwal, R. Amariglio, K. Papp and 14 more. Annals of Neurology, 2015

934 citations recorded by the source corpus.

Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease‐modifying therapies.

Subfields: Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/f190a1a6b576f8b64b228ebd3d4eb8692fcb46ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease (2017, background): “initiating role in early (pre-clinical) stages of the Alzheimer’s disease pathophysiological cascade, increasing the severity and rate of accumulation of tau aggregates (Price and Morris, 1999) and promoting tau spread beyond the medial temporal lobe into neocortex (Johnson et al., 2016; Schöll et a”
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease (2017, background): “(Brier et al., 2016; Johnson et al., 2016; Ossenkoppele et al., 2016), in contrast to weaker associations seen with Aβ.”
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a033118 5 ising (Maruyama et al. 2013; Xia et al. 2013; Okamura et al. 2014; Johnson et al. 2016), but they are not yet clinically available.”
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers (2016, background): “Because MRI, FDG, and tau PET topographic patterns map onto clinical phenotype, a different set of imaging signatures is needed to describe atypical variants of AD.”
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. (2016, positive): “In line with a recent study (Johnson et al., 2016), visual inspection and regional quantification of (18)FAV1451 images (Table 2 and Supplementary Fig.”
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease (2018, positive): “Furthermore, it has been reported that tau lesions occurred earlier than Aβ accumulation (Braak and Del Tredici, 2014; Johnson et al., 2015).”
PET Imaging of Tau Deposition in the Aging Human Brain (2016, positive): “The patterns of AV-1451 retention parallel findings in neuropathological studies (Braak and Braak, 1991, 1997; Serrano-Pozo et al., 2011), as well as a recent report indicating that the visual appearance of AV-1451 retention parallels Braak staging (Johnson et al., 2016).”
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, positive): “Today, the combination of CSF or PET Ab and tau biomarkers may best stratify low-risk and high-risk individuals [21], but imaging markers of Ab and tau provide additional information about spatial distribution and longitudinal changes (particularly for tau PET) that would allow an “in vivo” staging ”